Patients suffering from Triple Negative Breast Cancer with PD-L1 positive tumors can now be treated by atezolizumab (Tecentriq) and nab-paclitaxel (Abraxane).
Phase-III trials are looking at chemotherapy backbones in TNBC such as paclitaxel and platinum-based chemotherapy. Inhibitors like Atezolizumab and Keytruda are being researched to aid immunotherapy processes in case of breast cancer.
Atezolizumab is an end-point Inhibitor. IMpassion 130 Trial was performed to check its effect. Progression Free Survival (PFS) was for 7.5 months in case of nab-paclitaxel along atezolizumab and 5 months in case of chemotherapy alone. PFS was noted for a single year and it was 29% in case of Atezolizumab along Nab-paclitaxel and 16% if Nab-paclitaxel was taken alone.
Schmid revealed in an interview with OncLive that IMpassion 130 Trial had enrolled 902 patients to check the effect of end-point inhibitor for PFS. It’s the first kind of randomized the trial with a targeted therapy to demonstrate OS benefit. Four co-primary endpoints in the trial were present. 2 for PFS and 2 for OS, both in the Intent-to-treat population. 41% of patients were PD-L1 positive. Results of trial depicted that addition of Atezolizumab increased PFS and particularly OS in PD-L1 positive tumors. PD-L1 is an important biomarker in case of PD-L1 positive patients of TNBC and benefits the treatment whereas no such benefits are for PD-L1 negative patients.
Schmid says that this trial had clearly shown us the progressive role of immunotherapy in treatment for TNBC with PD-L1 positive tumors.